FY2020 Earnings Estimate for Sucampo Pharmaceuticals, Inc. (SCMP) Issued By Leerink Swann
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) – Investment analysts at Leerink Swann increased their FY2020 earnings estimates for Sucampo Pharmaceuticals in a report issued on Thursday. Leerink Swann analyst J. Schwartz now expects that the biopharmaceutical company will earn $1.58 per share for the year, up from their prior estimate of $1.57. Leerink Swann currently has a “Outperform” rating and a $15.00 price target on the stock. Leerink Swann also issued estimates for Sucampo Pharmaceuticals’ FY2021 earnings at $1.77 EPS.
A number of other equities research analysts have also recently issued reports on SCMP. BidaskClub cut Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 5th. Roth Capital set a $30.00 price objective on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Maxim Group restated a “buy” rating and set a $23.00 price objective (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a report on Tuesday, August 8th. TheStreet cut Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday, August 2nd. Finally, Mizuho cut Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $14.00 to $12.00 in a report on Tuesday. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Sucampo Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $17.86.
TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/06/fy2020-earnings-estimate-for-sucampo-pharmaceuticals-inc-scmp-issued-by-leerink-swann.html.
Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) traded down 0.95% during mid-day trading on Friday, reaching $10.45. The company had a trading volume of 777,677 shares. The firm’s 50-day moving average is $11.69 and its 200 day moving average is $10.73. The company’s market capitalization is $484.10 million. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.55.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The firm had revenue of $59.90 million during the quarter, compared to the consensus estimate of $56.44 million. During the same quarter in the prior year, the company earned $0.24 EPS. The firm’s revenue for the quarter was up 15.3% compared to the same quarter last year.
Hedge funds have recently modified their holdings of the stock. AlphaMark Advisors LLC boosted its stake in shares of Sucampo Pharmaceuticals by 25.4% in the second quarter. AlphaMark Advisors LLC now owns 98,400 shares of the biopharmaceutical company’s stock valued at $1,033,000 after buying an additional 19,900 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Sucampo Pharmaceuticals by 107.3% in the first quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock valued at $4,044,000 after buying an additional 190,292 shares during the period. Texas Permanent School Fund boosted its stake in shares of Sucampo Pharmaceuticals by 2.2% in the second quarter. Texas Permanent School Fund now owns 18,319 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 398 shares during the period. State of Tennessee Treasury Department bought a new stake in shares of Sucampo Pharmaceuticals in the first quarter valued at approximately $258,000. Finally, Royce & Associates LP boosted its stake in shares of Sucampo Pharmaceuticals by 24.6% in the first quarter. Royce & Associates LP now owns 974,023 shares of the biopharmaceutical company’s stock valued at $10,714,000 after buying an additional 192,000 shares during the period. Institutional investors and hedge funds own 55.44% of the company’s stock.
In related news, insider Jones W. Bryan purchased 4,700 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The stock was acquired at an average cost of $10.60 per share, for a total transaction of $49,820.00. Following the completion of the purchase, the insider now owns 4,700 shares in the company, valued at approximately $49,820. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jason Patrick Meyenburg purchased 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was bought at an average price of $12.13 per share, with a total value of $48,520.00. Following the completion of the purchase, the insider now owns 30,228 shares of the company’s stock, valued at approximately $366,665.64. The disclosure for this purchase can be found here. Insiders own 4.13% of the company’s stock.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.